Molecular characteristics of bronchioloalveolar carcinoma and adenocarcinoma, bronchioloalveolar carcinoma subtype, predict response to erlotinib by Miller Vincent A, Riely Gregory J, Zakowski Maureen F, Li Allan R, Patel Jyoti D, Heelan Robert T, Kris Mark G, Sandler Alan B, Carbone David P, Tsao Anne, Herbst Roy S, Heller Glenn, Ladanyi Marc, Pao William, Johnson David H in Journal of clinical oncology : official journal of the American Society of Clinical Oncology (2008).

[PMID: 18349398] PubMed


We conducted this phase II trial to determine the efficacy of erlotinib in patients with bronchioloalveolar carcinoma (BAC) and adenocarcinoma, BAC subtype, and to determine molecular characteristics associated with response.

[ hide abstract ]

Discussed In Paper


Variant Annotations

Sign in to see variant annotations.

Rx Annotations

No dosing information annotated.